deferoxamine and its cardiotoxicity effects
Phase 3
- Conditions
- acute and chronic cardiopathy.Heart disease, unspecified
- Registration Number
- IRCT2016080615666N5
- Lead Sponsor
- Vice chancellor of research, Shiaz Univeisity of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
signing informed consent; male or female aged between 2 to 18 years at screening; new pediatric cancer patients who are going to receive Anthracyclin drugs as part of their chemotherapy regimen
Exclusion criteria: patients below two years old; patients with previous history of treatment with any kind of chemotherapy or radiotherapy; diagnosis of congenital heart disease, preexisting heart failure and established renal disease
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cardiac Troponin-I. Timepoint: baseline, after the first dose of doxorubicin and after chemotherapy coarse. Method of measurement: hematology analysis.;NT-proBNP. Timepoint: baseline, after the first dose of doxorubicin and after chemotherapy coarse. Method of measurement: hematology analysis.;Cardiac indexes. Timepoint: baseline, 3 and 12 months intervals. Method of measurement: Conventional and tissue doppler echocardiography.
- Secondary Outcome Measures
Name Time Method